TiumBio: "Please call our endometriosis treatment 'Marigolicx' now"

Tiium Bio, a company specializing in the research and development of treatments for rare and intractable diseases, announced on the 21st that the World Health Organization (WHO) has approved the international nonproprietary name (INN) for its endometriosis treatment ‘TU2670’ as ‘merigolix’.

Huntaek Kim, CEO of Tium Bio

Merigolix is a compound word combining ‘Meri,’ which evokes ‘merry,’ meaning cheerful, lively, and energetic, and ‘golix,’ a suffix from the gonadotropin-releasing hormone (GnRH) antagonist class.

Tiium Bio is currently conducting a Phase 2a clinical trial of merigolix (TU2670) for a new endometriosis treatment in five European countries. Merigolix is known to attract interest from various global pharmaceutical companies due to its advantages, including excellent safety and the ability to effectively reduce estradiol hormone, which worsens endometriosis, even at lower doses compared to existing treatments.

Kim Hoon-taek, CEO of Tiium Bio, said, “We are pleased to have an international nonproprietary name for TU2670,” adding, “Based on the topline results of the Phase 2a clinical trial scheduled for the first half of next year in Europe, we will accelerate efforts to license merigolix to Europe and other regions to make it a new drug used by patients worldwide.”

GnRH antagonist class treatments are expected to be game changers that replace existing therapies due to their efficacy, safety, and convenience in treating female diseases such as endometriosis and uterine fibroids, as well as conditions like prostate cancer and precocious puberty. Market research firm GlobalData forecasts that the GnRH antagonist market will grow rapidly at an average annual rate of 47.4%, reaching a size of $1.9 billion (approximately 2.44 trillion KRW) by 2030 based on the major seven countries.

This content was produced with the assistance of AI translation services.